Systematic studies of a self-assembling peptide nanofiber scaffold with other scaffolds.
A designer self-assembling peptide nanofiber scaffold has been systematically studied with 10 commonly used scaffolds in a several week study using neural stem cells (NSC), a potential therapeutic source for cellular transplantations in nervous system injuries. These cells not only provide a good in vitro model for the development and regeneration of the nervous system, but may also be helpful in testing for cytotoxicity, cellular adhesion, and differentiation properties of biological and synthetic scaffolds used in medical practices. We tested the self-assembling peptide nanofiber scaffold with the most commonly used scaffolds for tissue engineering and regenerative medicine including PLLA, PLGA, PCLA, collagen I, collagen IV, and Matrigel. Additionally, each scaffold was coated with laminin in order to evaluate the utility of this surface treatment. Each scaffold was evaluated by measuring cell viability, differentiation and maturation of the differentiated stem cell progeny (i.e. progenitor cells, astrocytes, oligodendrocytes, and neurons) over 4 weeks. The optimal scaffold should show high numbers of living and differentiated cells. In addition, it was demonstrated that the laminin surface treatment is capable of improving the overall scaffold performance. The designer self-assembling peptide RADA16 nanofiber scaffold represents a new class of biologically inspired material. The well-defined molecular structure with considerable potential for further functionalization and slow drug delivery makes the designer peptide scaffolds a very attractive class of biological material for a number of applications. The peptide nanofiber scaffold is comparable with the clinically approved synthetic scaffolds. The peptide scaffolds are not only pure, but also have the potential to be further designed at the molecular level, thus they promise to be useful for cell adhesion and differentiation studies as well as for future biomedical and clinical studies.
Gelain
Fabrizio
F
Center for Biomedical Engineering NE47-379, Massachusetts Institute of Technology, Cambridge, MA 02139-4307, USA.
Lomander
Andrea
A
Vescovi
Angelo L
AL
Zhang
Shuguang
S
D001253:Astrocytes / Q000166:cytology / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D001672:Biocompatible Materials / Q000737:chemistry; D002448:Cell Adhesion / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D024042:Collagen Type I / Q000378:metabolism; D024141:Collagen Type IV / Q000378:metabolism; D004338:Drug Combinations; D019344:Lactic Acid / Q000378:metabolism; D007797:Laminin / Q000378:metabolism; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D009420:Nervous System / Q000166:cytology; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D009836:Oligodendroglia / Q000166:cytology / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D010455:Peptides / Q000378:metabolism*; D011091:Polyesters; D011100:Polyglycolic Acid / Q000378:metabolism; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D011509:Proteoglycans / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology / Q000502:physiology / Q000648:ultrastructure; D023822:Tissue Engineering
D001672:Biocompatible Materials; D024042:Collagen Type I; D024141:Collagen Type IV; D004338:Drug Combinations; D007797:Laminin; D010455:Peptides; D011091:Polyesters; D011108:Polymers; D011509:Proteoglycans; C059485:matrigel; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide); D003094:Collagen